Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02707666
Title A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Chicago
Indications

malignant pleural mesothelioma

Therapies

Pembrolizumab

Cisplatin + Pemetrexed Disodium

Age Groups: adult
Covered Countries USA


No variant requirements are available.